ReviewMedical2026

Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis.

Mariga C.; da Silva F.; Schiefler O.; Amazonas E.; Mateus A.; Schmidt C.; Filho S. · Frontiers in allergy · 2026

Research summary

**Background & Methods** This prospective study evaluated cannabis oil as adjunctive therapy in 16 dogs with atopic dermatitis that showed inadequate response to oclacitinib monotherapy. Dogs progressed through a fixed-sequence protocol with four evaluation stages: baseline oclacitinib alone (T0), placebo plus oclacitinib (T30), cannabis oil plus oclacitinib (T60), and cannabis oil plus 50% reduced oclacitinib dose (T90), with blinded dermatological assessments using CADESI-4 scoring and owner-reported pruritus scoring at each stage. **Key Findings** • Adjunctive cannabis oil significantly reduced pruritus compared to baseline oclacitinib monotherapy (T0 vs. T60: p=0.0010; T0 vs. T90: p=0.0025), though no significant difference was observed between placebo and cannabis oil treatments at T30 versus T60. • Pruritus control was maintained when oclacitinib dosage was reduced by 50% in conjunction with cannabis oil continuation (T90), suggesting potential for dose reduction within a multimodal treatment approach. • Objective dermatological assessment by CADESI-4 showed no statistically significant differences across treatment stages, despite owner-reported improvements in pruritus. **Dosage & Administration** Not reported. The study specifies cannabis oil formulation but does not provide specific dosing information, concentration, cannabinoid profile, or administration route/frequency. **Safety & Adverse Effects** Mild, transient, and self-limiting adverse events were reported by owners during both placebo (mineral oil) and cannabis oil treatment periods. No serious safety concerns were documented. The specific nature of adverse events is not detailed in the abstract. **Evidence Quality** This study has significant limitations: small sample size (n=14 completers), fixed-sequence design without randomization increasing bias risk, and lack of blinding for owners regarding treatment allocation. The disconnect between objective CADESI-4 findings (non-significant) and subjective pruritus scoring raises concerns about placebo effect or owner bias despite reported blinding. Absence of cannabis oil dosing details limits reproducibility and clinical applicability. This represents preliminary evidence (level 3-4) suggesting cannabis warrants further investigation, but robust randomized controlled trials with objective outcome measures are needed before clinical recommendations can be established.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
Frontiers in allergy
Year
2026
Study type
Review
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home